Daiwa Securities Group Inc. Purchases 3,880 Shares of DexCom, Inc. (NASDAQ:DXCM)

Daiwa Securities Group Inc. raised its position in DexCom, Inc. (NASDAQ:DXCM) by 5.0% during the fourth quarter, Holdings Channel reports. The fund owned 80,979 shares of the medical device company’s stock after acquiring an additional 3,880 shares during the period. Daiwa Securities Group Inc.’s holdings in DexCom were worth $6,298,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of DXCM. Forvis Mazars Wealth Advisors LLC increased its position in shares of DexCom by 0.7% during the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company’s stock valued at $1,359,000 after purchasing an additional 118 shares during the last quarter. Principal Securities Inc. boosted its holdings in shares of DexCom by 3.4% in the fourth quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock worth $316,000 after buying an additional 135 shares during the last quarter. Larson Financial Group LLC grew its position in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after buying an additional 137 shares during the period. Crossmark Global Holdings Inc. increased its holdings in DexCom by 1.0% during the third quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock valued at $1,259,000 after buying an additional 182 shares during the last quarter. Finally, GPS Wealth Strategies Group LLC raised its position in DexCom by 13.2% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company’s stock worth $123,000 after acquiring an additional 185 shares during the period. Institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In other news, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 45,083 shares of company stock worth $3,826,604. Insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

DXCM has been the subject of a number of recent research reports. Canaccord Genuity Group boosted their price objective on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Morgan Stanley raised their price objective on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Citigroup boosted their price objective on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday, March 4th. Finally, Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and raised their target price for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $99.82.

DexCom Trading Up 0.7 %

Shares of DexCom stock opened at $70.76 on Thursday. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The firm has a market cap of $27.65 billion, a price-to-earnings ratio of 49.48, a PEG ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The business has a 50-day moving average price of $84.39 and a 200-day moving average price of $76.93.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.